select trial glp 1 glp-1 Semaglutide and the Heart: clinical insights from the SGLTi and GLP-1 in HF – Inclusion and exclusion criteria for

Yalanmaya bal olarak ortaya kan salk sorunlaryla beraber, damar hastalklar, kanser, bunama gibi kronik hastalklarn oluumunda serbest radikallerin etkisi olduka yksektir

Charles EF, Lambert CG, Kerner B

Novo: ~16%), and Eli Lilly has proven its ability to scale production quickly

Avoid Harsh Products: Refrain from using strong skincare products, exfoliants, or retinoids for a few days after the treatment

GLP-1 RAs STEP 1 (2021) : Semaglutide 2.4 ./ 14.9% 68 2.4% (Wilding et al., 2021, NEJM) SURMOUNT-1 (2022) : Tirzepatide (GLP-1/GIP dual agonist) 15 ./ 20.9% (Jastreboff et al., 2022, NEJM) GLP-1 HbA1c () 2 (Hypoglycemia) Glucose-dependent LEADER (liraglutide) SUSTAIN-6 (semaglutide) 2024 FDA Semaglutide (Wegovy) FLOW (2024) semaglutide (MASLD/NAFLD) GLP-1 RAs GLP-1

Protect from direct sunlight or extreme temperatures